tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

AMRN Stock Latest News

Amarin announces presentation of research on clinical impact of VASCEPA/VAZKEPA
The FlyAmarin announces presentation of research on clinical impact of VASCEPA/VAZKEPA
11d ago
AMRN
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
PremiumPress Releases
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
11d ago
AMRN
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
PremiumPress Releases
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
29d ago
AMRN
Amarin announces new data from REDUCE-IT trial, abstracts
PremiumThe Fly
Amarin announces new data from REDUCE-IT trial, abstracts
29d ago
AMRN
Amarin reports Q2 adjusted EPS 1c, consensus (4c)
PremiumThe Fly
Amarin reports Q2 adjusted EPS 1c, consensus (4c)
2M ago
AMRN
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
PremiumPress ReleasesAmarin Reports Second Quarter 2024 Financial Results and Provides Business Update
2M ago
AMRN
Amarin Announces New CEO Aaron Berg and Incentive Plan
Premium
Company Announcements
Amarin Announces New CEO Aaron Berg and Incentive Plan
2M ago
8K
AMRN
AMRN Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
AMRN Earnings this Week: How Will it Perform?
2M ago
AMRN
Amarin gets reimbursement approval for Vazkepa in Portugal
PremiumThe Fly
Amarin gets reimbursement approval for Vazkepa in Portugal
2M ago
AMRN
Amarin gets reimbursement approval for Vazkepa in Portugal
PremiumThe Fly
Amarin gets reimbursement approval for Vazkepa in Portugal
2M ago
AMRN
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
PremiumPress Releases
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
2M ago
AMRN
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
PremiumPress Releases
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
2M ago
AMRN
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
PremiumPress ReleasesAmarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
2M ago
AMRN
Amarin announces partner EddingPharm received regulatory approval for VASCEPA
Premium
The Fly
Amarin announces partner EddingPharm received regulatory approval for VASCEPA
2M ago
AMRN
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
3M ago
EQ
VIR
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
4M ago
EQ
AFMD
Amarin Leadership Changes Amidst VASCEPA Coverage Challenge
PremiumCompany Announcements
Amarin Leadership Changes Amidst VASCEPA Coverage Challenge
4M ago
8K
AMRN
Amarin says ‘large’ Commercial PBM transitioning Vascepa to not covered
PremiumThe Fly
Amarin says ‘large’ Commercial PBM transitioning Vascepa to not covered
4M ago
AMRN
Amarin Board of Directors Announces CEO Transition
PremiumPress Releases
Amarin Board of Directors Announces CEO Transition
4M ago
AMRN
Amarin announces resignation of CEO Holt, Berg to succeed
PremiumThe FlyAmarin announces resignation of CEO Holt, Berg to succeed
4M ago
AMRN
 Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
Premium
Press Releases
 Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
4M ago
AMRN
Amarin announces Greek Ministry of Health approved VAZKEPA for reimbursement
Premium
The Fly
Amarin announces Greek Ministry of Health approved VAZKEPA for reimbursement
4M ago
AMRN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >